menu
    • menu
    [{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Private Placement","leadProduct":"Sulbactam","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Durlobactam","moa":"Beta-lactamases A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Not Applicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Private Placement","leadProduct":"Sulbactam","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Intravenous infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sulbactam","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entasis Therapeutics \/ Zai Lab Limited","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Zai Lab Limited"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sulbactam","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Entasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Sulbactam","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sulbactam","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sulbactam","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Sulbactam","moa":"Acinetobacter baumannii enzyme","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sulbactam","moa":"Acinetobacter baumannii enzyme","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sulbactam","moa":"Beta lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Innoviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sulbactam","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Not Applicable"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sulbactam","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Innoviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sulbactam","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Not Applicable"},{"orgOrder":0,"company":"Innoviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sulbactam","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innoviva \/ Not Applicable"},{"orgOrder":0,"company":"Innoviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sulbactam","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innoviva \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Durlobactam

    Menu

    Durlobactam

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Innoviva

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Innoviva

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Ac...

                            Details : Xacduro (sulbactam & durlobactam), co-packaged for intravenous use, which act as beta-lactamase inhibitor, approved in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneum...

                            Brand Name : Xacduro

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 18, 2023

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Innoviva

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Innoviva

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for...

                            Details : Xacduro (sulbactam for injection; durlobactam for injection), combination of sulbactam, a beta-lactam antibacterial, and durlobactam, a beta-lactamase inhibitor, approved for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneum...

                            Brand Name : Xacduro

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 23, 2023

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Innoviva

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Innoviva

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee

                            Details : ETX2514 is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a rationally designed broad-spectrum IV β-lactamase inhibitor, being developed for the treatment of infections due to Acinetobacter aumanniicalcoaceticus complex.

                            Brand Name : ETX2514

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 17, 2023

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Entasis Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Entasis Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Innoviva

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigationa...

                            Details : ETX2514 or SUL-DUR is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a rationally designed broad-spectrum IV β-lactamase inhibitor, being developed for the treatment of infections due to Acinetobacter aumanniicalcoaceticus com...

                            Brand Name : ETX2514

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 13, 2023

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Innoviva

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Innoviva

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Innoviva

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulbactam,Durlobactam,Imipenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-D...

                            Details : SUL-DUR is an IV, investigational drug that is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a rationally designed broad-spectrum IV BLI, being developed for the treatment of infections caused by ABC, including carbapenem-resis...

                            Brand Name : SUL-DUR

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 30, 2022

                            Lead Product(s) : Sulbactam,Durlobactam,Imipenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Entasis Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Entasis Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulbactam,Durlobactam,Imipenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark P...

                            Details : Sulbactam-Durlobactam (SUL-DUR) is an IV, investigational drug that is combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, novel broad-spectrum IV BLI, developed for treatment of infections caused by ABC complex, including carbapenem-r...

                            Brand Name : ETX2514sul

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 19, 2022

                            Lead Product(s) : Sulbactam,Durlobactam,Imipenem

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Entasis Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Entasis Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWe...

                            Details : Sulbactam (SUL-DUR) is a β-lactam antibiotic with activity against Acinetobacter baumannii; however, β-lactamase-mediated resistance to sulbactam is now widespread rendering it generally ineffective.

                            Brand Name : SUL-DUR

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2022

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Entasis Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Entasis Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Innoviva

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Innoviva Completes Acquisition of Entasis Therapeutics

                            Details : Entasis brings to Innoviva an exciting portfolio that includes potentially first- and best-in-class medicines for the treatment of multidrug-resistant Gram-negative bacteria, including lead asset SUL-DUR.

                            Brand Name : SUL-DUR

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 11, 2022

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Innoviva

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Entasis Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Entasis Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Confe...

                            Details : The primary efficacy endpoint, 28-day all-cause mortality (ACM) in carbapenem resistant Acinetobacter baumannii-calcoaceticus (CRABC) m-MITT cohort (n=125) was 19.0% (12/63) and 32.3% (20/62) for SUL-DUR versus colistin, respectively (difference -13.2% [...

                            Brand Name : SUL-DUR

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 26, 2022

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Entasis Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Entasis Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference

                            Details : SUL-DUR (Sulbactam-durlobactam), is the first investigational drug to demonstrate efficacy in a 28-day all-cause mortality trial focused on carbapenem-resistant Acinetobacter, an “Urgent” threat as designated by the CDC.

                            Brand Name : SUL-DUR

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 18, 2022

                            Lead Product(s) : Sulbactam,Durlobactam

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth